Hyloris Pharmaceuticals SA (52U.F)

11,40 0,00 (0,00%) Ab 08:22AM CEST. Markt geöffnet.

Hyloris Pharmaceuticals SA

Boulevard Patience et Beaujonc N°3/1
Liège 4000
Belgium
32 4 346 02 07
https://hyloris.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Stijn Van Rompay	Co-Founder, CEO & Director	N/A	N/A	1977
Mr. Thomas Jacobsen	Co-Founder, Chief Business Development Officer & Executive Director	N/A	N/A	1976
Mr. Jean-Luc Vandebroek	Chief Financial Officer	N/A	N/A	1973
Dr. Dietmar Aichhorn Ph.D.	Chief Operating Officer	N/A	N/A	N/A
Mr. Sven Watthy	Investor Relations Manager & Communications manager	N/A	N/A	1991
Mr. Koenraad Van Der Elst	Chief Legal Officer	N/A	N/A	1962

Die Beträge haben den Stand und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health and other major therapeutic areas. It offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease. The company provides Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative non-opioid pain management; Tranexamic acid RTU, an antifibrinolytic drug for the formation of blood clots; Miconazole/Domiphen Bromide, a topical synergistic combination treatment for Recurrent Vulvovaginal Candidiasis; AlenuraTM, a first-line drug treatment for acute pain in interstitial cystitis/bladder pain syndrome; and Plecoid Agent IV for the treatment of acute myeloid leukemia and small cell lung cancer. It also offers Atomoxetine, an oral liquid for the treatment of patients with attention deficit hyperactivity disorder; HY-029, a liquid formulation of an antiviral drug to treat viral infections; HY-083, a nasal spray for the treatment of idiopathic rhinitis; and HY-088, an oral liquid that treats hypophosphatemia. The company was incorporated in 2012 and is headquartered in Liège, Belgium.

Corporate Governance

Hyloris Pharmaceuticals SAs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.